Key result
Intravenous amiodarone is a promising agent that should be considered for use in patients with shock-refractory ventricular arrhythmias, as other ACLS drugs lack proven survival benefits.
Why the study?
Does intravenous amiodarone improve survival in patients with shock-refractory ventricular arrhythmias during cardiac arrest?
Does intravenous amiodarone improve survival in patients with shock-refractory ventricular arrhythmias during cardiac arrest?
Answers are grounded in this paper and cite their sources.
Intravenous amiodarone should be considered for shock-refractory ventricular arrhythmias in cardiac arrest, despite the lack of definitive survival benefit from controlled trials for ACLS-recommended antiarrhythmics.
Antiarrhythmic drugs currently recommended in the American Heart Association's Advanced Cardiac Life Support (ACLS) guidelines for the treatment of cardiac arrest have not been proved in controlled clinical trials to improve survival in patients with ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT). Intravenous amiodarone is a promising agent for the treatment of VF and VT. Based on available evidence, amiodarone should be considered for use in patients with shock-refractory ventricular arrhythmias.
No takes yet. Share an insight, caveat, or question.
Kudenchuk et al. (1999) conducted a review in Cardiac arrest, ventricular fibrillation, or pulseless ventricular tachycardia. Intravenous amiodarone was evaluated on Survival. Intravenous amiodarone is a promising agent that should be considered for use in patients with shock-refractory ventricular arrhythmias, as other ACLS drugs lack proven survival benefits.
Synapse has enriched 10 related papers. Consider them for comparative context: